Sugi Predict

Sugi Predict / Compounds / SCHEMBL176952

SCHEMBL176952

SCHEMBL176952

Cc1n[nH]c2cc(O)ccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.59
▸ HSP90AB1 P08238 1/20 0.59
▸ ESR1 P03372 1/20 0.56
▸ FGFR1 P11362 3/20 0.49
▸ FGFR2 P21802 2/20 0.49
▸ FGFR3 P22607 1/20 0.49
▸ KDM4E B2RXH2 4/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ HPGD P15428 4/20 0.46
▸ ADORA2A P29274 1/20 0.46
▸ ADORA2B P29275 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAPK1 P28482 2/20 0.45
▸ MAP2K4 P45985 1/20 0.45
▸ MAPKAPK2 P49137 1/20 0.45
▸ MAPKAPK3 Q16644 1/20 0.45
▸ MAPK6 Q16659 1/20 0.45
▸ MAPKAPK5 Q8IW41 1/20 0.45
▸ MEN1 O00255 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907451 0.85 FGFR1 (0.70) PDPK1HSP90AB1ESR1FGFR1FGFR2
SCHEMBL23062796 0.84 MAP2K4 (0.53) PDPK1HSP90AB1ESR1FGFR1FGFR2
Tert-Butyl Formate SCHEMBL27819524 0.83 PDPK1 (0.44) PDPK1HSP90AB1ESR1FGFR1FGFR2
SCHEMBL12907435 0.81 CHEK1 (0.58) PDPK1HSP90AB1ESR1FGFR1FGFR2
SCHEMBL12247 0.79 ITK (0.53) ADORA2AADORA2BMAPK1MAP2K4MAPKAPK2
SCHEMBL31552439 0.79 ITK (0.53) ADORA2AADORA2BMAPK1MAP2K4MAPKAPK2
SCHEMBL10130804 0.78 PDPK1 (0.61) PDPK1HSP90AB1ESR1FGFR1FGFR2
SCHEMBL8212257 0.76 MAP2K4 (0.56) ADORA2AADORA2BMAPK1MAP2K4MAPKAPK2
SCHEMBL588513 0.76 AXL (0.50) PDPK1FGFR1FGFR2KDM4EADORA2A
SCHEMBL21937470 0.76 ADORA2A (0.46) PDPK1HSP90AB1ESR1FGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105734586-B A kind of organic-silicon-modified corrosion inhibitor and preparation method thereof 中国石油化工股份有限公司 2018-04-10 — — CN claimed
CN-105734586-A Organosilicon-modified corrosion inhibitor and preparation method thereof 中国石油化工股份有限公司 2016-07-06 — — CN claimed
EP-3704094-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-11 — — EP disclosed
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2025-04-17 — — US disclosed
US-20240166652-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-05-23 — — US disclosed
EP-4356971-A2 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2024-04-24 — — EP disclosed
CN-115947681-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2023-04-11 — — CN disclosed
US-20220363678-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2022-11-17 — — US disclosed
CN-109641844-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2022-11-01 — — CN disclosed
CN-112189008-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2021-01-05 — — CN disclosed
US-20200361941-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2020-11-19 — — US disclosed
CN-1606544-A Bicyclic compounds ASAHI CHEMICAL IND (JP) 2005-04-13 — — CN disclosed
US-20050038069-A1 Substituted azabicyclic compounds AVENTIS PHARMA LIMITED (GB) 2005-02-17 — — US disclosed
US-20050020602-A1 Bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2005-01-27 — — US disclosed
US-6800645-B1 INHIBIT PRODUCTION OR PHYSIOLOGICAL EFFECTS OF TNF, INHIBIT CYCLIC AMP PHOSPHODIESTERASE AVENTIS PHARMA LIMITED (GB) 2004-10-05 — — US disclosed
EP-1447400-A1 BICYCLIC COMPOUND Asahi Kasei Pharma Corporation (JP) 2004-08-18 — — EP disclosed
US-20020173527-A1 Substituted azabicyclic compounds ASTLES PETER CHARLES (GB) 2002-11-21 — — US disclosed
EP-0934307-A1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE RHONE-POULENC RORER LIMITED (GB) 1999-08-11 — — EP disclosed
WO-1998005327-A1 SUBSTITUTED AROMATIC COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-02-12 — — WO disclosed
WO-1997048697-A1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE RHONE-POULENC RORER LIMITED (GB) 1997-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361941-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PDPK1 337/4885HSP90AB1 158/4885ESR1 1100/4885
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PDPK1 337/4885HSP90AB1 158/4885ESR1 1100/4885
US-20020173527-A1 Substituted azabicyclic compounds CBR1, NOX1, POR PDPK1 3656/4885HSP90AB1 2409/4885ESR1 2274/4885
US-20050038069-A1 Substituted azabicyclic compounds NR2C2, NR3C1, NR3C2 PDPK1 4723/4885HSP90AB1 3178/4885ESR1 379/4885
US-20050020602-A1 Bicyclic compound GOT1, H1-0, HSD11B1 PDPK1 3514/4885HSP90AB1 4096/4885ESR1 471/4885
US-20240166652-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PDPK1 337/4885HSP90AB1 158/4885ESR1 1100/4885
US-20220363678-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 PDPK1 337/4885HSP90AB1 158/4885ESR1 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.